Beranda › Penyakit Graft-versus-Host › Florida
Uji klinis Penyakit Graft-versus-Host di Florida
7 studi untuk Penyakit Graft-versus-Host mencari peserta di lokasi di Florida.
Kota di Florida
Teks studi resmi (Bahasa Inggris)
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- University of Miami, Miami
Menerima pesertaFase 1/2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05531786Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
- University of Miami Sylvester Comprehensive Cancer Center, Miami
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06910969Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
- Moffitt Cancer Center, Tampa
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT06450925Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Moffitt Cancer Center, Tampa
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT07216443A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- University of Miami, Miami
Menerima pesertaFase 2
Usia 2 ke atas · Semua jenis kelamin · Diperbarui 16 Jun 2026 · NCT04710576A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- University of Miami, Miami
- Moffitt Cancer Center, Tampa
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Mei 2026 · NCT06615050A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- AdventHealth Orlando, Orlando
- Moffitt Cancer Center, Tampa
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Des 2025 · NCT06619561Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.